BRCC3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro

Table 1 Correlation between the clinicopathologic features and expression of BRCC3

		BRCC3
Characteristics	N	Low expression	High expression	χ ²	P values
Gender
Male	77	41	36	1.030	0.310^a
Female	23	15	8	1.030	0.310^a
Age
<45	47	27	20	0.075	0.784 ^a
≥45	53	29	24	0.075	0.784 ^a
Histological classification
Type II	8	5	3	0.149	0.699 ^b
Type III	92	51	41	0.149	0.699 ^b
Clinical stage
I-II	56	25	31	6.662	0.010 ^a*
III-IV	44	31	13	6.662	0.010 ^a*
T
T1-T2	66	39	27	0.753	0.386 ^a
T3-T4	34	17	17	0.753	0.386 ^a
N
N0	60	39	21	4.931	0.026 ^a*
N1-N3	40	17	23	4.931	0.026 ^a*
M
M0	83	52	31	8.764	0.003 ^a *
M1	17	4	13	8.764	0.003 ^a *
Relapse
Yes	14	8	6	0.009	0.926 ^a
No	86	48	38	0.009	0.926 ^a
Skull-based invasion
Yes	20	11	9	0.010	0.920 ^a
No	80	45	35	0.010	0.920 ^a

ISSN: 1748-717X